Background: ZBTB33, also known as Kaiso, is a member of the zinc finger and BTB/POZ family. In contrast to many transcription factors, ZBTB33 has the ability to bind both a sequence-specific consensus and methylated DNA. Although these dual binding preferences enable ZBTB33 to function as an active as well as repressive regulator of gene expression, little is known about the underlining molecular mechanisms. Results: In this study, we aimed to investigate the role of ZBTB33 as a methylated DNA binding factor. We took advantage of the latest releases of the ENCODE sequencing datasets, including ZBTB33 ChIPseq, whole genome bisulfite sequencing (WGBS), histone mark ChIP-seq and sequencing assays determining the chromatin states, to characterize the chromatin landscapes surrounding methylated ZBTB33 binding sites. Interestingly, our integrative analyses demonstrated that the majority of methylated ZBTB33 binding sites were located within condensed chromatin, which are inaccessible to DNase I and Tn5 transposase. Moreover, these sites were carrying a newly revealed histone post-translational modification signature, with significant enrichment of mono-methylation at lysine 4 of histone 3 (H3K4me1) and a complete absence of other active or expected repressive histone marks. Conclusions: Overall, our analyses revealed that ZBTB33 has the unique ability to bind methylated DNA across heterochromatin in a transition state, suggesting a potential role for ZBTB33 in heterochromatin priming.
this ability remains unclear. By comparing a previous release of ENCODE ZBTB33 ChIP-seq dataset with WGBS and reduced representation bisulfite sequencing (RRBS) in GM12878 and K562 cell lines, respectively, a recent study by Blattler et al. concluded that ZBTB33 binds predominantly non-methylated DNA [15] . However, the ChIP-seq datasets used in these analyses were sequenced at a low depth of coverage in both cell lines (36nt single-end read and less than 20 million reads in each replicate, Supplementary Table 1 and 2) and, the antibody quality has not fully fulfilled the ENCODE Consortium standards while absolved by an ENCODE Antibody Review Committee (Supplementary Table 1 Table 1 and 2). Moreover, due to the limitation of genome sequencing coverage in RRBS experiments, the characterization of the DNA methylation status of ZBTB33 binding sites in K562 cells was restricted to approximately 4% of CpG sites in the genome, primarily located in gene promoters and CpG islands [16] . To extend Blattler et al. study, we performed methylation profiling of ZBTB33 binding sites in K562 using WGBS, which also revealed hypomethylated ZBTB33 bound promoters, while a small portion of hypermethylated ZBTB33 binding sites located in introns (Supplementary Figure 1) .
The latest ZBTB33 ChIP-seq datasets in K562 and GM12878 cells released by ENCODE have shown a significant increase in antibody quality (both antibody primary and secondary tests are compliant to the current ENCODE standards, ENCODE Antibody ID: ENCAB292USO), library quality and reproducibility (Supplementary Tables 2-4 , Supplementary Figure 2 ), encouraging us to perform a novel ZBTB33 binding sites / DNA methylation integrative analysis to determine the methylation status of ZBTB33 binding sites. In this K562 ChIP-seq release, we identified approximately nine times more ZBTB33 binding sites (25, 170 peaks) compared to the previous experiment (2,740 peaks), with a slight overlap between the two experiments (Supplementary Figure 3) . Finally, the overall methylation status for ZBTB33 narrow peak regions were profiled as hypermethylated in K562, while in GM12878 the CpG sites within ZBTB33 peaks can be either hyper-or hypomethylated (Supplementary Figure 4) . Our analysis shows a different DNA methylation profile compared to the Blatter et al. results, which is mainly due to the distinct ZBTB33 peak sets identified between the two studies (Supplementary Figure 3) . However, given the improved quality in the latest release of the ZBTB33 ChIP-seq in both cell lines (Supplementary Table   2 ), we suggest that peak sets derived from our analysis better describe the genome-wide occupancy of ZBTB33 binding sites. That is the reason why we decided to perform a new integrative analysis of ZBTB33 binding sites with epigenomic features using the latest ENCODE datasets in both cell lines.
We performed a de novo motif discovery using MEME-ChIP [17] and peak-motifs module from RSAT package [18] in K562 and GM12878 (Supplementary Figure 5) . in K562 and GM12878 (Supplementary Figure 5) . Similar motifs were discovered in K562 and GM12878 using the same tool, while the motif discovery results in both cell lines were not consistent between MEME and RSAT. The difficulty in de novo motif discovery may be due to the atypical intrinsic sequences surrounding ZBTB33 peak centers, overrepresented in CG and GC dinucleotides while underrepresented in other dinucleotide contents in both cell lines (Supplementary Figure 6) . Therefore, we decided to rely on the ZBTB33 motif TCTCGCGAGA described and validated by Raghav et al. [19] . Indeed, in this study, the authors proved high binding affinities of ZBTB33 to the methylated palindromic sites in vitro, even higher than the sequence-specific consensus Kaiso binding site (KBS) TCCTGCNA, and further showed in detail that methylation in the core CGCG is crucial for the binding affinity while the flanking sequences play an important role. Consequently, we searched for the known ZBTB33 binding motif (TCTCGCGAGA) [19] with a position weight matrix downloaded from JASPAR (JASPAR ID: MA0527.1) across all identified peaks using the matrix-scan module from RSAT [20] . The ZBTB33 binding motif TCTCGCGAGA was found to be centrally enriched around ZBTB33 peak centers in both cell lines, while the top three motifs discovered by MEME were either not as centrally enriched as TCTCGCGAGA or not conserved across cell lines (Supplementary Figure 7) . Further spatial correlation analyses between the genome-wide TCTCGCGAGA sites and ZBTB33 peaks by GenometriCorr [21] and regioneR [22] revealed a significantly high overlap between the two genomic intervals in both cell lines, corroborating a high enrichment of the known ZBTB33 motif in the peak regions (Supplementary Table 5 Table 7) , confirming the validity of the ChIP-seq experiments. Overall, ZBTB33 binding sites were located mostly within introns or intergenic regions in terms of peak number (Supplementary Figure 9) . However, when normalized according to the length of different genomic features, ZBTB33 binding sites were revealed to be more enriched in gene promoters in both cell lines, suggesting a direct role in gene regulation (Supplementary Table 8 and 9 ). DNA methylation levels within ZBTB33 binding sites were not distributed homogenously across the genome.
Indeed, binding sites in intronic and intergenic regions were found to be highly methylated, while in promoter loci, a considerable portion of CpG sites bound by ZBTB33 were unmethylated ( Figure 1B ). As described previously [9] , our analysis confirms that ZBTB33 has the ability to bind both methylated and unmethylated DNA. When comparing ZBTB33 binding properties in the two cell lines, we observed that most of ZBTB33 binding sites were not conserved across cell lines (16,272 out of 16,954 and 1,375 out of 2,057 ZBTB33 binding sites are cell specific in K562 and GM12878 respectively -Supplementary Figure   10 ). Interestingly, the 682 ZBTB33 binding sites common to both cell lines shared similar DNA methylation patterns, with a high level of methylated ZBTB33 binding sites, particularly located within intronic peaks (Supplementary Figure 10) . The main difference that we can observe across these two cell lines is a distinct methylation profile on ZBTB33 bound promoters, which are more hypermethylated in K562 and hypomethylated in GM12878. This difference is probably due to a distinct chromatin and epigenetic landscape across cell lines (Chronic myeloid leukemia cell -K562 versus B lymphocyte -GM12878), which leads to different binding properties.
To further investigate the chromatin landscapes of methylated and unmethylated ZBTB33 binding sites, we considered all CpG sites within the motif that had a methylation level greater than 90% as methylated binding sites. Conversely, unmethylated binding sites were defined as the loci where CpG methylation levels were less than 10%. These stringent thresholds allowed us to avoid mis-scoring DNA methylation on ZBTB33 binding sites due to cell heterogeneity. In other words, choosing extreme cut-offs helped us to focus our analysis only on loci highly homogenous in term of DNA methylation. With these thresholds and settings described in the methods section, we identified 3,522 highly methylated ZBTB33 binding sites and 266 unmethylated sites in K562, and 802 highly methylated ZBTB33 binding sites and 505 unmethylated sites in GM12878 ( Figure 1A) Figure 1C ). This observation suggests that ZBTB33 ChIP-seq peaks found within methylated DNA loci contain more ZBTB33 direct binding sites compared to peaks detected across unmethylated DNA loci [23] . Interestingly, the ZBTB33 binding motif showed a high level of conservation in these methylated CpG sites, implying a strong selection pressure for these bases ( Figure   1D ). Finally, we found that the sequence-specific consensus KBS TCCTGCNA, previously characterized by in vitro assays [8] , was not enriched neither in ZBTB33 K562 nor GM12878 ChIP-seq peaks (Supplementary Figure 11) .
ZBTB33 binding domains are associated with genes involved in chromatin regulation
We annotated both methylated and unmethylated ZBTB33 binding sites according to their respective chromatin contexts and functions using the previous systemic annotations performed in K562 and GM12878 by the Broad Institute (ChromHMM: Chromatin state discovery and characterization) [24] . Most [25] . In addition, gene ontology (GO) analysis of target genes of ZBTB33 methylated regulatory elements computed by the Genomic Regions Enrichment of Annotation Tool (GREAT) [26] , revealed a significant enrichment of terms relative to epigenetic regulation of gene expression, nucleosome organization and histone lysine methylation in K562 (Figure 2 ), which suggests an important role of ZBTB33 in chromatin modulation. The limited number of peaks in ZBTB33 ChIP-seq experiment in GM12878 did not allow us to confirm this results in this cell line. In contrast, no significant GO term was found for unmethylated binding sites, probably because of the low number of loci.
Co-occupancy of transcription factors surrounding ZBTB33 binding sites
To identify the potential protein complex associated with ZBTB33, we analyzed K562 and GM12878 ENCODE ChIP-seq profiles, including 187 and 114 transcription factors with more than 30 million uniquely map reads in K562 and GM12878 respectively, surrounding methylated and unmethylated ZBTB33 binding sites. For all these transcription factors, only one significant binding event (MLLT1) was detected surrounding methylated ZBTB33 binding sites in both cell lines (Figure 3 left) . Interestingly, MLLT1, also known as ENL, is a critical component of the super elongation complex and also a histone acetylation reader [27] . The co-occupancy of MLLT1 with ZBTB33 in methylated binding sites suggests the potential of transcriptional regulation in these regions. No significant signal was found surrounding methylated ZBTB33 binding sites within the ENCODE ChIP-seq datasets of transcription factors sequenced with less than 30 million uniquely map reads (34 for K562 and 18 for GM12878, Supplementary Figure 13 left). This analysis shows that, within methylated DNA, ZBTB33 does not commonly exit as a member of a protein or regulatory complex but presumably binds to its DNA targets solitarily in most instances, a feature that ZBTB33 shares with pioneer transcription factors [28] . In contrast, considerable co-occupying events were detected surrounding unmethylated ZBTB33 binding Remarkably, in K562, the cluster 3 included the histone lysine demethylase PHF8, suggesting a role for ZBTB33 in removing the di-methyl group of lysine 9 in histone H3 (H3K9me2) [29, 30] . In addition, the fact that MAX and RBFOX2 belonged to cluster 3 in K562 indicates that ZBTB33 may be included in protein complexes regulating cell proliferation as well as apoptosis and EMT [31, 32] .
Unfortunately, PHF8 and RBFOX2 ChIP-seq datasets were not available for GM12878. However, ZBTB33-MAX co-binding was confirmed in GM12878. Finally, ZBTB33 binding sites also co-localized with the insulator protein CTCF (cluster 1 for K562 and cluster 3 for GM12878), and further analyses using the TFBS cluster database from UCSC (c.f. methods section) confirmed that approximately 29% and 43% of ZBTB33 binding sites co-localized with CTCF in K526 and GM12878 cells respectively, corroborating a previous study [25] (Supplementary Figure 14, Supplementary Tables 10 and 11 ).
ZBTB33 binds predominantly heterochromatin loci harboring a primed chromatin histone signature
To characterize chromatin landscapes associated with ZBTB33 binding events in conjunction with DNA methylation levels, we integrated ZBTB33 ChIP-seq results with ENCODE datasets from various histone modifications, RNA polymerase II activities and chromatin states in K562 and GM12878 cells. 
Discussion
During the recent decades, DNA methylation has commonly been associated with transcriptional repression. However, this correlation is not as strict as previously assumed, and emerging iconoclastic evidence has revealed an increasing number of transcription factors with the ability to bind methylated DNA [35] [36] [37] . These observations suggest a more complex interplay between DNA gene expression and DNA methyl-modification that is dependent on the methylcytosine context. Accumulating evidence supports the hypothesis that TFs serve as methylated-CpG readers at enhancers or within regions of low CpG density, while methyl-CpG-binding domain proteins are prone to recognize densely methylated DNA sites [38] . ZBTB33 is one of the TFs which have been recognized with the ability to bind methylated DNA.
It has been reported that at least two symmetrically methylated CpG dinucleotides are required to be bound by ZBTB33 in vitro [39] , while a recent in vitro study showed that one methylated CpG is even necessary and sufficient for ZBTB33 recognition [40] . Indeed, the newly deposited ZBTB33 ChIP-seq datasets have revealed approximately 60% methylated ZBTB33 binding sites possess the methylated CGCG core motif in both cell lines, while the rest contain either only one methylated CpG site or more than one, but not consecutive CpGs. ZBTB33 that binds methylated DNA is primarily described as a transcription repressor [41] . Nevertheless, the mechanism of the repression exerted by ZBTB33 when binding methylated DNA is still not well depicted. Yoon et al. proposed a model in which ZBTB33 is associated with nuclear receptor corepressor (N-coR), to form a "Kaiso/N-coR" complex and bind methylated promoters to foster histone deacetylation and, consequently, the formation of repressive chromatin structures [42] . However, at the genome scale, our analyses in K562 and GM12878 cells do not confirm the co-occupancy of N-coR and ZBTB33 across methylated DNA. This mechanism might be cell cycle specific and hardly detectable via ChIP-seq assays performed in an unsynchronized cell population. Interestingly, ZBTB33 is also able to function as a methyl-dependent activator [43] . H3K4me1 was termed "a window of opportunity" by Eliezer and Joanna [47] in which enhancer activation is possible, followed by nucleosome removal and H3K27ac deposition. This function is reminiscent of territory occupied by pioneer factors, which uncompact the heterochromatin and initiate the recruitment of the transcriptional machinery [28] . However, further investigations are required to fully categorize ZBTB33 as a pioneer factor. Nonetheless, our analyses have illuminated new evidence supporting ZBTB33 priming of heterochromatin and potentially playing a role in the modulation of chromatin topology.
Conclusions
Altogether, our bioinformatics analysis has discovered a unique role of ZBTB33 and this is through its ability to bind a specific motif within methylated and compacted DNA. Remarkably, ZBTB33 methylated binding sites are associated with a distinctive histone signature, where only H3K4me1 appears to be enriched. Although ZBTB33 binding sites are clearly located within condensed nucleosome loci, the 1 0 histone code associated with ZBTB33 binding sites is incompatible with a canonical heterochromatin state, which requires a H3K9me3 enrichment to associate the HP1-Lamin B1 receptor complex [48] .
Therefore, we suggest that ZBTB33 is involved in the inducement or the maintenance of a new characterized chromatin state, transitional between repressed and active form. Moreover, we found that H3K4me1 marks primed DNA loci not only in euchromatin as previously described [49] , but also in heterochromatin.
Methods

ZBTB33 ChIP-seq peak calling
ZBTB33 ChIP-seq dataset as well as K562 and GM12878 DNA input files were downloaded from the ENCODE consortium website (https://www.encodeproject.org, Supplementary Table 1 and 3) and reads in raw files were aligned to the hg38 genome assembly using STAR with the following parameters: --outFilterMultimapNmax 1, --outFilterMatchNminOverLread 0.80 and blocked splice function [50] . For peak calling, we used MACS2 [51] with default parameters and the irreproducible discovery rate (IDR) pipeline, as recommended by the ENCODE consortium [52] , to assess the consistency between replicates.
Motif identification surrounding peak regions
Motif de novo discovery was performed using MEME-ChIP package with default parameters [17] in a േ 100bp window size surrounding peak summits and peak-motifs module in RSAT package with oligo, position and local-word analyses [18] in a േ 500bp window size surrounding peak summits. Further, the RSAT motif discovery results underwent motif clustering using matrix-clustering module with default parameters [53] .
For the known ZBTB33 motif scan, extended peak sequences (േ4 kb surrounding peak summits) were scanned with the ZBTB33 position-specific weight matrix (PSWM) downloaded from JASPAR [54] (JASPAR ID: MA0527.1) using the RSAT matrix-scan module with a Markov model of order 1 as a background model, and a p-value threshold set to 
Methylation states in ZBTB33 binding sites
To observe DNA methylation profiles at ZBTB33 binding sites, whole genome bisulfite sequencing (WGBS) raw datasets in K562 and GM12878 were downloaded from the ENCODE consortium (Supplementary Table 12 using the ratio between all methylated-cytosine read number to total read number within the region, across both replicates as described previously by Adusumalli et al. [61] . We considered a region with a beta score greater than 90% as a homogeneously methylated binding site and a region with a beta score less than 10% as a homogeneously unmethylated binding site, while a binding site with an in-between beta score (more than 10% and less than 90%) is considered heterogeneously methylated across the cell population. In GM12878, we were constrained to use only one replicate due to the low amount of ZBTB33
ChIP-seq peaks. Indeed, only 789 peaks are covered by 5 reads X 2. Among them, 317 are methylated (beta score greater than 90%) and 160 unmethylated (beta score less than 10%). Methylation levels of CpGs within ZBTB33 binding sites in GM12878 cells were computed as explained previously on loci covered by a least 5 reads in one replicate (i.e., 5 reads X 1, Supplementary Table 12 ). We used the Fisher's exact test to support that the occurrences of ZBTB33 motif matches surrounding methylated and unmethylated ZBTB33 peaks (േ100 bp around peak centers) were significantly higher than the occurrences of permuted motifs (control). Furthermore, to validate a more central enrichment of ZBTB33 motif surrounding the methylated sites compared to the unmethylated loci, we assessed the difference in proportions, between the methylated and unmethylated ZBTB33 binding sites located exactly at the peak centers (േ15 bp around peak centers), using the Fisher's exact test.
Peak annotation in the genomic location context of ZBTB33 binding sites
To confirm the genomic location of ZBTB33 binding sites, we utilized the annotatePeaks function from the HOMER package [62] , where the nearest transcription start site is assigned for each peak. The annotations include, but are not limited to, promoters (defined from -1 kb to +100 bp), transcription termination sites (defined from -100 bp to +1 kb), coding DNA sequence exons, 5' UTR exons, 3' UTR exons, introns, and intergenic regions.
Gene ontology analysis of ZBTB33 target genes
The genomic regions enrichment of annotations tool (GREAT) [26] was used to predict functions of ZBTB33 target genes. Because GREAT is restricted to the analysis of sequencing experiments performed in the hg19 assembly, we converted our ZBTB33 ChIP-seq peaks coordinates from hg38 to hg19 using the LiftOver program hosted at the UCSC genome browser website (http://genome.ucsc.edu/cgi-bin/hgLiftOver, Supplementary Tables 14 and   15 ). In order to compare H3K4me1 enrichment surrounding the CpGs found in methylated ZBTB33
binding sites with genome-wide all methylated CpGs as well as the CpGs found in unmethylated ZBTB33
binding sites, H3K4me1 read intensities, normalized by sequencing depth, were accordingly extracted in a 5bp window size surrounding them and further underwent the inverse hyperbolic sine transformation.
The co-occupancy of transcription factors associated with un/methylated ZBTB33 binding sites was calculated using 221 and 132 ChIP-seq raw datasets in K562 and GM12878 respectively, downloaded from the ENCODE consortium website (Supplementary Table 16 ). After a read base quality check and read trimming when necessary using Trimmomatic [63], ChIP-seq reads were aligned to the human genome reference hg38 using STAR with the following parameters: --outFilterMultimapNmax 1, --outFilterMatchNminOverLread 0.80 and blocked splice function [50] . We segregated these ChIP-seq assays into two groups according to the number of unique map reads. ChIP-seq assays with more than 30 million unique map reads were considered high quality, and ChIP-seq assays with less than 30 million unique map reads were considered lower quality.
Heatmap files of read intensities normalized by sequencing depth in the ±5kb regions surrounding ZBTB33 binding sites were generated with the annotatePeaks module from the HOMER package using a resolution of 25 bp, to portray the chromatin and epigenetic landscapes. Similar strategy as aforementioned was employed to profile the co-occupancy of transcription factors surrounding ZBTB33 un/methylated binding sites in a ±500 bp window size with a resolution of 5 bp. In addition, the fold enrichment of each transcription factor at ZBTB33 binding sites was calculated as the ratio of the average read intensity in the ±100 bp region surrounding the peak center to the average read intensity in a 200 bp window located 300 bp away from the peak center. Hierarchical clustering and heatmap plots were processed using the heatmap.2 function from the R gplots library (https://cran.rproject.org/web/packages/gplots/index.html).
Integration of K562 un/methylated ZBTB33 binding sites with ChromHMM and ENCODE TFBS clusters
ENCODE TFBS clusters v3 and ChromHMM files were downloaded from the UCSC genome browser (https://genome.ucsc.edu, Supplementary Table 17 ). Since ENCODE TFBS clusters and Broad
ChromHMM are restricted to the hg19 genome assembly, we used the LiftOver program from UCSC (http://genome.ucsc.edu/cgi-bin/hgLiftOver) to convert our ZBTB33 ChIP-seq peaks from the hg38 to the hg19 release (Supplementary Table 13 ).
We defined a region of േ 100 bp surrounding each ZBTB33 un/methylated peak summit as its peak region. 
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